Bristol Myers Squibb's KarXT shows improvement in Alzheimer's psychosis symptoms in open-label Phase 3 studies
BMY•Bristol Myers Squibb presented preliminary Phase 3 data showing KarXT improved hallucinations, delusions and overall disease severity in Alzheimer's-associated psychosis. Results covered ADEPT-1's 12-week open-label period and ADEPT-3's 52-week extension; the trials remain ongoing, and double-blind results are still blinded.
1. Preliminary study findings
Bristol Myers Squibb presented descriptive analyses showing KarXT improved hallucinations, delusions and overall disease severity in Alzheimer's-associated psychosis. The data came from ADEPT-1's 12-week open-label period and ADEPT-3's 52-week extension, and were presented at the Clinical Trials on Alzheimer's Disease Conference.
2. Safety and trial status
KarXT was generally well tolerated across both studies, with no new safety signals identified. The ADEPT trials remain ongoing, and their double-blind results are still blinded.




